Skip to main content

Day: April 6, 2022

Chr. Hansen Holding A/S Interim Report Q2 2021/22

Company announcement no. 03/2022 April 6, 2022 Strong Q2 growth in a challenging environment Statement by CEO Mauricio Graber: “In a challenging environment, Chr. Hansen continued its strong growth trajectory, delivering 14% organic growth in the second quarter. Growth in Health & Nutrition further accelerated, supported by Human Health, while Food Cultures & Enzymes showed solid growth, mainly driven by its core segments and developed markets. In the second quarter, the EBIT margin b.s.i. increased to 27.7% thanks to strong volume growth. The performance in the first half of the year provides a robust foundation for delivering on our ambitions for the full year. However, overall market volatility has increased due to the accelerating inflationary pressure and the Russian invasion of Ukraine. We are responding to the higher cost...

Continue reading

Proactive news headlines including PVW Resources, Emperor Energy, GTI Resources and Meeka Gold

Sydney, April 06, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:PVW Resources NL (ASX:PVW) has secured commitments from existing and new institutional and high net-worth investors to raise $9.5 million in a heavily oversubscribed placement to advance its Tanami REE Project in the Kimberley region of Western Australia. Click here Emperor Energy Ltd (ASX:EMP) has surged on delivering a 50% gas resource increase to 1.848 Tcf (trillion cubic feet) at its Vic/P47 Permit within the Judith Gas Field offshore Gippsland Basin in Victoria. Click here GTI Resources Ltd (ASX:GTR) will pick up nearly 14,000 acres worth of contiguous ISR uranium exploration claims in Wyoming’s Great Divide Basin. Click here Meeka Gold Ltd (ASX:MEK)...

Continue reading

EUROBIO SCIENTIFIC: MAINTAINING HIGH LEVEL RESULTS IN 2021

MAINTAINING HIGH LEVEL RESULTS IN 2021Total turnover of €184.7m Growth in non-COVID activities (+14%) Strong EBITDA at €78m Increased cash generation at €66m (€55m in 2020) Cash position at €102m and decrease in financial debt (€11m) Acceleration of strategic deployment focused on proprietary products, international development, and new market segmentsParis, April 6, 2022 –7h30 Eurobio Scientific (FR0013240934, ALERS), a leading French group in specialty in vitro medical diagnostics, presents today its 2021 consolidated annual results, established according to French accounting standards and approved by the company’s board of directors which met on April 5, 2022.1. In 2021, Eurobio Scientific maintained a high level of turnover and results, combining a strong activity related to the diagnosis of COVID in a context of strong reduction...

Continue reading

Caledonia Mining Corporation Plc: Appointment of Joint Broker

ST HELIER, Jersey, April 06, 2022 (GLOBE NEWSWIRE) — Caledonia Mining Corporation Plc (“Caledonia” or the “Company”) (NYSE AMERICAN: CMCL; AIM: CMCL; VFEX: CMCL) is pleased to announce the appointment of Liberum Capital Limited as its joint broker with immediate effect. Enquiries:Caledonia Mining Corporation PlcMark LearmonthCamilla Horsfall Tel: +44 1534 679 802Tel: +44 7817 841793   WH IrelandAdrian Hadden/ Jessica Cave/ Andrew De Andrade Liberum Capital LimitedScott Mathieson/Kane Collings Tel: +44 20 7220 1751 Tel: +44 20 3100 2000   BlytheRay Financial PRTim Blythe/Megan Ray Tel: +44 207 138 3204   3PPBPatrick ChidleyPaul Durham Tel: +1 917 991 7701Tel: +1 203 940 2538   Curate Public Relations (Zimbabwe)Debra Tatenda Tel: +263 77280 2131

Continue reading

Corbion published agenda for AGM

Corbion has published its agenda for the upcoming Annual General Meeting of Shareholders (AGM) to be held on 18 May 2022. The full AGM agenda together with explanatory notes is available on Corbion’s website under Investor relations –> Shareholder information –> Shareholder meetings.AttachmentPress release AGM_agenda_ENG_2022

Continue reading

Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders

New Series of Potent and Selective Compounds Identified Using Proprietary Allosteric Modulator Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, April 6, 2022 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it has moved a selective and potent M4 muscarinic receptor positive allosteric modulator (PAM) program into lead optimization. M4 PAMs have the potential to treat schizophrenia and other types of debilitating neuropsychiatric disorders. “There is a strong and robust rationale for developing novel schizophrenia therapeutics by targeting allosteric sites of muscarinic receptor sub-types, particularly M4, based on growing scientific evidence,” noted Jean-Philippe...

Continue reading

TGS Announces a Second 3D Multi-Client Seismic Survey in the Egyptian Red Sea

OSLO, Norway (28 February 2022) – TGS, a global provider of energy data and intelligence, today announced a new 3D seismic survey in the Red Sea, Egypt, in partnership with Schlumberger. This survey represents the second phase of new acquisition for the partners in this region and will encompass a minimum of 5,000 square kilometers. Data will be acquired with long offsets and processed using a Pre-Stack Depth Migration (PSDM) workflow to enable subsalt imaging. The acquisition is expected to start in April 2022, with final products anticipated in mid-2023 to ensure availability ahead of future license rounds in the region. Egypt’s attractive, stable investment climate, enhanced by established exploration infrastructure and complemented by regular, transparent, and well-managed licensing rounds, has helped bolster interest in...

Continue reading

Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025Both parties strengthening focus on antibiotic stewardship and planning to engage in AMR surveillance and efforts to repurpose existing antibiotics.Collaboration focuses on next-generation sequencing (NGS) and AI-assisted bioinformatics solutions for surveillance and drug repurposing effortsBasel, April 6, 2022 — Sandoz today announces the extension and expansion until January 31, 2025 of its strategic collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR). The extension of the existing master services agreement with Ares, a subisidiary of OpGen Inc, reflects...

Continue reading

InterCure Reports Record Breaking Q4 and 2021 Results – Exceeded Preliminary Results

Another record year with continued industry leading growth and profitability supported by focused strategy and execution Revenue growth expected to continue in the first quarter and throughout 2022 Strong balance sheet with $89 million cash supporting future profitable growth NEW YORK and TORONTO and HERZLIYA, Israel, April 05, 2022 (GLOBE NEWSWIRE) — InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) (“InterCure” or the “Company”) is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2021. References herein to “preliminary results” refer to the preliminary results published by the Company on February 8, 2022. All amounts are expressed in New Israeli Shekels (NIS) or Canadian dollars ($), unless otherwise noted. Fourth Quarter 2021 Key Financial...

Continue reading

Brookfield Renewable Announces Intention to Redeem its Series 11 Preferred Units

BROOKFIELD, News, April 05, 2022 (GLOBE NEWSWIRE) — Brookfield Renewable Partners L.P. (TSX: BEP.UN; NYSE: BEP) today announced that it intends to redeem all of its outstanding Class A Preferred Limited Partnership Units, Series 11 (the “Series 11 Preferred Units”) (TSX: BEP.PR.K) for cash on April 30, 2022. The redemption price for each Series 11 Preferred Unit will be C$25.00. Holders of Series 11 Preferred Units of record as of April 14, 2022 will receive the previously declared final quarterly distribution of C$0.3125 per Series 11 Preferred Unit. Brookfield Renewable operates one of the world’s largest publicly traded, pure-play renewable power platforms. Our portfolio consists of hydroelectric, wind, solar and storage facilities in North America, South America, Europe and Asia, and totals approximately 21,000 megawatts of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.